Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP266
MIFTS: 57

Hypoxia

Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hypoxia

About this section

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia 53 17 71

External Ids:

UMLS 71 C0242184
Sources

Summaries for Hypoxia

About this section
Novus Biologicals : 55 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to chronic mountain sickness and renal cell carcinoma, nonpapillary, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hypoxia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Metformin and Zinc have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and endothelial, and related phenotypes are Decreased viability and Decreased viability

NINDS : 53 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Wikipedia : 74 Hypoxia is a condition in which the body or a region of the body is deprived of adequate oxygen supply... more...

Sources

Related Diseases for Hypoxia

About this section

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1432)
# Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 32.1 PDK1 EGLN3
2 renal cell carcinoma, nonpapillary 32.0 VHL MTOR HIF1AN HIF1A EPAS1 EGLN3
3 acute mountain sickness 31.4 VHL HIF1AN HIF1A EGLN1
4 polycythemia 30.9 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
5 pheochromocytoma 30.8 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
6 paraganglioma 30.6 VHL HIF1A EPAS1 EGLN1
7 kidney cancer 30.5 VHL PDK1 MTOR HIF1A EPAS1
8 hemangioblastoma 30.4 VHL HIF1A EPAS1
9 clear cell renal cell carcinoma 30.3 VHL MTOR HIF1A EPAS1 EP300 EGLN3
10 pheochromocytoma-paraganglioma 30.0 VHL EGLN2 EGLN1
11 fumarate hydratase deficiency 30.0 VHL HIF1A
12 erythrocytosis, familial, 2, autosomal recessive 29.9 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
13 primary polycythemia 29.8 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
14 retinal hemangioblastoma 29.8 VHL HIF1A EPAS1
15 acquired polycythemia 29.7 EPAS1 EGLN1
16 cerebral hypoxia 12.7
17 pulmonary hypertension owing to lung disease and/or hypoxia 12.4
18 respiratory underresponsiveness to hypoxia and hypercapnia 12.3
19 polycythemia due to hypoxia 12.3
20 anoxia 11.9
21 neonatal hypoxic and ischemic brain injury 11.8
22 asphyxia neonatorum 11.7
23 exudative vitreoretinopathy 1 11.6
24 pulmonary edema 11.5
25 apnea of prematurity 11.5
26 severe acute respiratory syndrome 11.4
27 hantavirus pulmonary syndrome 11.4
28 congenital extrahepatic portosystemic shunt 11.4
29 tempi syndrome 11.4
30 methemoglobinemia due to deficiency of methemoglobin reductase 11.3
31 pneumothorax, primary spontaneous 11.1
32 methemoglobinemia and ambiguous genitalia 11.1
33 exudative vitreoretinopathy 2, x-linked 11.1
34 exudative vitreoretinopathy 4 11.1
35 exudative vitreoretinopathy 5 11.1
36 exudative vitreoretinopathy 6 11.1
37 exudative vitreoretinopathy 7 11.1
38 leukostasis 11.1
39 congenital laryngeal palsy 11.1
40 typical congenital nemaline myopathy 11.1
41 lung cancer susceptibility 3 11.0
42 pulmonary hypertension 11.0
43 sleep apnea 10.9
44 ischemia 10.9
45 polycystic kidney disease 10.8
46 glioblastoma multiforme 10.7
47 glioma 10.7
48 glial tumor 10.7
49 pulmonary hypertension, primary, 1 10.7
50 pre-eclampsia 10.6

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia
Sources

Symptoms & Phenotypes for Hypoxia

About this section

UMLS symptoms related to Hypoxia:


seizures, fever, dyspnea, edema, cachexia, vertigo, hemoptysis, apnea, headache, syncope, cyanosis, chills, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, cheyne-stokes respiration, coughing, hoarseness, increased sweating, anoxemia, signs and symptoms, respiratory, sneezing, hyperoxia, motor symptom, skin symptoms, physical symptom, physical appearance, body

GenomeRNAi Phenotypes related to Hypoxia according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.05 MTOR
2 Decreased viability GR00055-A-2 10.05 MTOR
3 Decreased viability GR00173-A 10.05 HIPK2
4 Decreased viability GR00221-A-1 10.05 MTOR PDK1 VHL
5 Decreased viability GR00221-A-2 10.05 EGLN3 EP300 HIPK2 PDK1 VHL
6 Decreased viability GR00221-A-3 10.05 PDK1
7 Decreased viability GR00221-A-4 10.05 MTOR
8 Decreased viability GR00240-S-1 10.05 PSMA7
9 Decreased viability GR00249-S 10.05 ARNT CITED2 EGLN3 PSMA7 VHL
10 Decreased viability GR00301-A 10.05 EGLN3 HIPK2 VHL
11 Decreased viability GR00342-S-1 10.05 MTOR
12 Decreased viability GR00342-S-2 10.05 MTOR
13 Decreased viability GR00381-A-1 10.05 EGLN2 EGLN3 HIF1AN PSMA7
14 Decreased viability GR00386-A-1 10.05 ARNT TIGAR
15 Decreased viability GR00402-S-2 10.05 EGLN1 EGLN3 HIF3A HIPK2 KMT2A PSMA7

MGI Mouse Phenotypes related to Hypoxia:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 homeostasis/metabolism MP:0005376 10.4 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 cellular MP:0005384 10.37 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
4 growth/size/body region MP:0005378 10.34 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
5 embryo MP:0005380 10.31 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
6 hematopoietic system MP:0005397 10.29 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
7 immune system MP:0005387 10.26 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
8 mortality/aging MP:0010768 10.25 ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
9 muscle MP:0005369 10.22 EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
10 craniofacial MP:0005382 10.2 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
11 liver/biliary system MP:0005370 10.11 ARNT EGLN1 EGLN2 EGLN3 EPAS1 HIF1A
12 nervous system MP:0003631 10.06 ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
13 normal MP:0002873 9.91 ARNT CITED2 EGLN3 EP300 HIF1A HIF1AN
14 neoplasm MP:0002006 9.85 ARNT EP300 HIF1A KMT2A TIGAR VHL
15 renal/urinary system MP:0005367 9.85 ARNT CITED2 EGLN1 EP300 HIF1A HIPK2
16 respiratory system MP:0005388 9.56 CITED2 EGLN1 EP300 EPAS1 HIF1A HIF1AN
17 vision/eye MP:0005391 9.23 CITED2 EGLN3 EP300 EPAS1 HIF1A HIPK2
Sources

Drugs & Therapeutics for Hypoxia

About this section

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 725)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Bromhexine Approved Phase 4 3572-43-8
4
Succinylcholine Approved Phase 4 306-40-1 5314
5
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
6
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
8
Terbutaline Approved Phase 4 23031-25-6 5403
9
Insulin lispro Approved Phase 4 133107-64-9
10
Insulin glargine Approved Phase 4 160337-95-1
11
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
12
Methazolamide Approved Phase 4 554-57-4 4100
13
Caffeine Approved Phase 4 58-08-2 2519
14
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
15
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
16
Bisoprolol Approved Phase 4 66722-44-9 2405
17
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
18
Adenosine Approved, Investigational Phase 4 58-61-7 60961
19
Dipyridamole Approved Phase 4 58-32-2 3108
20
Ibuprofen Approved Phase 4 15687-27-1 3672
21
Budesonide Approved Phase 4 51333-22-3 63006 5281004
22
Nifedipine Approved Phase 4 21829-25-4 4485
23
Ranibizumab Approved Phase 4 347396-82-1 459903
24
Cetirizine Approved Phase 4 83881-51-0 2678
25
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
26
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
27
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
28
Desflurane Approved Phase 4 57041-67-5 42113
29
Riociguat Approved Phase 4 625115-55-1
30
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
31
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
32
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
33
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
34
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
35
Lopinavir Approved Phase 4 192725-17-0 92727
36
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
37
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
38
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
39
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
40
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
41
Benzydamine Approved Phase 4 100-46-9, 642-72-8 7504
42
Promethazine Approved, Investigational Phase 4 60-87-7 4927
43
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
44
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
45
Linagliptin Approved Phase 4 668270-12-0 10096344
46
Captopril Approved Phase 4 62571-86-2 44093
47
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
48
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
49
Ramipril Approved Phase 4 87333-19-5 5362129
50
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763

Interventional clinical trials:

(show top 50) (show all 2231)
# Name Status NCT ID Phase Drugs
1 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
2 Sevoflurane-based Volatile Induction and Maintenance of Anaesthesia (VIMA) Strategy Decreases the Risk of Postoperative Delirium in Elderly Patients With Registered Cerebral Hypoxemia Episodes During General Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
3 Comparison of Three Different Rates of Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Coblation Tonsillectomy or Adeno-tonsillectomy in Children Unknown status NCT02205580 Phase 4 continuous intravenous sufentanil 0.02μg•kg－1•h－1 infusion;continuous intravenous sufentanil 0.03μg•kg－1•h－1 infusion;continuous intravenous sufentanil 0.04μg•kg－1•h－1 infusion
4 Home Oxygen Therapy in the Ambulatory Treatment of Bronchiolitis Unknown status NCT01216553 Phase 4
5 Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC Unknown status NCT02525380 Phase 4
6 Phase 3 Study of Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage Unknown status NCT01180192 Phase 4 oxygen
7 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
8 Does the Early Use of Sodium Bicarbonate Improve Results of Cardiopulmonary Resuscitation Following Out-of-Hospital Cardiac Arrest - a Prospective, Controlled Clinical Trial Unknown status NCT01377337 Phase 4 sodium bicarbonate
9 Colloid Preload Versus Colloid Coload in Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Section Deliveries: A Prospective, Randomized, Double-Blind Comparative Study Unknown status NCT02393196 Phase 4 hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®);hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)
10 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
11 Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT Unknown status NCT02233790 Phase 4 Ticagrelor;Clopidogrel
12 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
13 Influence on Incidence of Postoperative Delirium by Various Sedatives in Elderly Patients With Hip Fracture Under Lumbar Anesthesia: A Randomized, Control and Multi-center Trial Unknown status NCT03346226 Phase 4 Dexmedetomidine Hydrochloride;Propofol
14 Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1) Unknown status NCT02798068 Phase 4 Solu-medrol or placebo administration
15 A Multicenter Study to Evaluate the Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
16 Continuous Positive Airway Pressure for Treatment of Postoperative Hypoxemia in Liver Transplant Unknown status NCT00510770 Phase 4
17 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
18 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
19 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
20 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
21 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
22 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function Completed NCT00517725 Phase 4 carvedilol;bisoprolol;Nebivolol
23 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
24 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
25 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4 100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
26 The Influence of Cerebral Blood Flow and Alkalosis on Neuromuscular Function During Environmental Stress Completed NCT01830335 Phase 4 Indomethacin;Placebo
27 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue. Completed NCT02758470 Phase 4 Acetazolamide;Methazolamide
28 The Use of Statins for Myocardial Death Prevention: From Cell to Bedside Completed NCT00772564 Phase 4 Atorvastatin
29 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
30 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
31 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
32 Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
33 Hyperoxia: An Unrecognized Mechanism for Inducing "Hypoxia-Like" Symptoms Completed NCT03268590 Phase 4 Oxygen
34 Can Muscle Dysfunction in COPD be Altered by Oxygenation in Patients With Intermittent Hypoxia on Exertion? Completed NCT01722370 Phase 4 Oxygen;Medical air equivalent
35 Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia Completed NCT03192488 Phase 4 Cetirizine;Placebo oral capsule
36 Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects. Completed NCT01377051 Phase 4 Indacaterol maleate;Placebo
37 Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study): A Investigator-initiated, Control- Randomized, Phase IV Multicenter Study Completed NCT01103336 Phase 4 pretreatment with intravenous nicorandil vs. placebo before coronary angiography
38 Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study Completed NCT01997515 Phase 4 Ketamine;placebo
39 Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4 placebo;Carvedilol;Nebivolol
40 Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation Completed NCT02962999 Phase 4 Ketamine;Saline
41 Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management Completed NCT01710891 Phase 4
42 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
43 Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea Completed NCT02160223 Phase 4 Sugammadex;Neostigmine
44 Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial Completed NCT02497729 Phase 4
45 CPAP Effect on Nocturnal Evolution of Chemosensitivity Determinants in Sleep Apnea-hypopnea Patients With Isolated Nocturnal Hypertension or Day-nigh Sustained Hypertension Completed NCT02398032 Phase 4
46 Multicenter, Prospective, Randomised, Open-label Study, Evaluating the Effect of Two Levels of Haemoglobin on Quality of Life and Speed of Progression of Renal Insufficiency on Renal Transplanted Patients With Chronic Graft Dysfunction (CGD) Completed NCT00396435 Phase 4 Neorecormon
47 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V Completed NCT00563121 Phase 4
48 Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography Completed NCT02171910 Phase 4 Doxapram;Placebo
49 Effect of Neuromuscular Blockade and Reversal by Sugammadex Versus Neostigmine on Breathing When Hypoxic or Hypercapnic in Volunteers Completed NCT02845375 Phase 4 Sugammadex;Neostigmine;Placebo
50 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. Completed NCT00500396 Phase 4

Search NIH Clinical Center for Hypoxia

Sources

Genetic Tests for Hypoxia

About this section
Sources

Anatomical Context for Hypoxia

About this section

MalaCards organs/tissues related to Hypoxia:

40
Brain, Lung, Endothelial, Heart, Liver, Kidney, Breast
Sources

Publications for Hypoxia

About this section

Articles related to Hypoxia:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Prokineticin 2 relieves hypoxia/reoxygenation-induced injury through activation of Akt/mTOR pathway in H9c2 cardiomyocytes. 61
31899964 2020
2
Protective effect of hypoxia inducible factor-1α gene therapy using recombinant adenovirus in cerebral ischaemia-reperfusion injuries in rats. 61
32432963 2020
3
Hypoxia regulates human mast cell adhesion to fibronectin via the PI3K/AKT signaling pathway. 61
32427041 2020
4
Long term hypoxia during gestation alters perirenal adipose tissue gene expression in the lamb. 61
32403966 2020
5
Long non-coding RNA DANCR alleviates hypoxia-caused H9c2 cells damage through up regulation of HIF-1α. 61
32041436 2020
6
Ocean acidification, hypoxia and warming impair digestive parameters of marine mussels. 61
32447113 2020
7
Offspring of rats with cerebral hypoxia-ischemia manifest cognitive dysfunction in learning and memory abilities. 61
32209770 2020
8
miR-210 is induced by hypoxia and regulates neural cell adhesion molecule in prostate cells. 61
31975433 2020
9
Hypoxia-mediated changes in bone marrow microenvironment in breast cancer dormancy. 61
32479768 2020
10
Exosomes in hypoxia-induced remodeling of the tumor microenvironment. 61
32473240 2020
11
Hypoxia-induced epithelial to mesenchymal transition in cancer. 61
32470488 2020
12
Hypoxia: Turning vessels into vassals of cancer immunotolerance. 61
32470491 2020
13
Role of ion channels in chronic intermittent hypoxia-induced atrial remodeling in rats. 61
32417371 2020
14
Therapeutic mechanism of human neural stem cell-derived extracellular vesicles against hypoxia-reperfusion injury in vitro. 61
32437794 2020
15
Hypoxia responsiveness linked variant in EGLN1 gene is enriched in oral cancer patients. 61
32464411 2020
16
Midazolam contributes to neuroprotection against hypoxia/reoxygenation-induced brain injury in neonatal rats via regulation of EAAT2. 61
32433937 2020
17
Hypoxia and cancer related pathology. 61
32439418 2020
18
Hypoxia modifies the response to flutamide and linuron in male three-spined stickleback (Gasterosteus aculeatus). 61
32247919 2020
19
The effects of hypoxia on aerobic metabolism in oil-contaminated sea bass (Dicentrarchus labrax). 61
32278192 2020
20
Wearable non-invasive monitors of diabetes and hypoxia through continuous analysis of sweat. 61
32312464 2020
21
Pum2 mediates Sirt1 mRNA decay and exacerbates hypoxia/reoxygenation-induced cardiomyocyte apoptosis. 61
32437714 2020
22
Effects of leptin on HPG axis and reproductive function in male rat in simulated altitude of 5500 m hypoxia environment. 61
32560810 2020
23
Fear memory is impaired in hypobaric hypoxia: Role of synaptic plasticity and neuro-modulators in limbic region. 61
32188570 2020
24
Insulin ameliorates hypoxia-induced autophagy, endoplasmic reticular stress and apoptosis of myocardial cells: In vitro and ex vivo models. 61
32360347 2020
25
MEIS1 regulated proliferation and migration of pulmonary artery smooth muscle cells in hypoxia-induced pulmonary hypertension. 61
32450174 2020
26
Protective effects of resveratrol and SR1001 on hypoxia-induced pulmonary hypertension in rats. 61
31973589 2020
27
MicroRNA-130a targeting hypoxia-inducible factor 1 alpha suppresses cell metastasis and Warburg effect of NSCLC cells under hypoxia. 61
32450163 2020
28
Hypoxia and pancreatic ductal adenocarcinoma. 61
32380129 2020
29
Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a. 61
32394311 2020
30
Hypoxia attenuate ionic transport in the isolated gill epithelium of Carcinus maenas. 61
32333115 2020
31
Corticosterone, Adrenal, and the Pituitary-Gonadal Axis in Neonatal Rats: Effect of Maternal Separation and Hypoxia. 61
32459830 2020
32
MiR-181a-5p is involved in the cardiomyocytes apoptosis induced by hypoxia-reoxygenation through regulating SIRT1. 61
32290769 2020
33
Hypoxia‑inducible factor‑1α regulates Lipin1 differently in pre‑adipocytes and mature adipocytes. 61
32319636 2020
34
Hypercapnia potentiates HIF-1α activation in the brain of rats exposed to intermittent hypoxia. 61
32305676 2020
35
Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. 61
32452915 2020
36
Hypoxia-induced lncRNA RP11-390F4.3 promotes epithelial-mesenchymal transition (EMT) and metastasis through upregulating EMT regulators. 61
32353468 2020
37
The clinical utility of imaging methods used to measure hypoxia in cervical cancer. 61
32286849 2020
38
Knockdown of HIF1A-AS2 suppresses TRIM44 to protect cardiomyocytes against hypoxia-induced injury. 61
32222118 2020
39
Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α. 61
32369776 2020
40
Hypoxia causes sex-specific hepatic toxicity at the transcriptome level in marine medaka (Oryzias melastigma). 61
32480175 2020
41
The role of a lncRNA (TCONS_00044595) in regulating pineal CLOCK expression after neonatal hypoxia-ischemia brain injury. 61
32448507 2020
42
Inhibiting the interaction between apoptosis-inducing factor and cyclophilin A prevents brain injury in neonatal mice after hypoxia-ischemia. 61
32277944 2020
43
Vitexin, an inhibitor of hypoxia-inducible factor-1α, enhances the radiotherapy sensitization of hyperbaric oxygen on glioma. 61
31677055 2020
44
Hypoxia regulates the differentiation and anti-tumor effector functions of γδT cells in oral cancer. 61
32255193 2020
45
1H NMR-based metabolomic analysis of cuttlefish, Sepia pharaonis (Ehrenberg, 1831) exposed to hypoxia stresses and post-anoxia recovery. 61
32305752 2020
46
Cysteine becomes conditionally essential during hypobaric hypoxia and regulates adaptive neuro-physiological responses through CBS/H2S pathway. 61
32184133 2020
47
DGKζ depletion attenuates HIF-1α induction and SIRT1 expression, but enhances TAK1-mediated AMPKα phosphorylation under hypoxia. 61
32224048 2020
48
Vitamin C decreases VEGF expression levels via hypoxia‑inducible factor‑1α dependent and independent pathways in lens epithelial cells. 61
32377733 2020
49
G-CSF attenuates neuroinflammation and neuronal apoptosis via the mTOR/p70SK6 signaling pathway in neonatal Hypoxia-Ischemia rat model. 61
32246916 2020
50
Glycyrrhizic acid exerts protective effects against hypoxia/reoxygenation-induced human coronary artery endothelial cell damage by regulating mitochondria. 61
32509013 2020
Sources

Variations for Hypoxia

About this section
Sources

Expression for Hypoxia

About this section
Search GEO for disease gene expression data for Hypoxia.
Sources

Pathways for Hypoxia

About this section

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Cellular Senescence (REACTOME) 65
Show member pathways
 13.08 VHL PSMA7 MTOR HIF3A HIF1AN HIF1A
2
Pathways in cancer 36
12.84 VHL MTOR HIF1A EPAS1 EP300 EGLN3
3
ErbB signaling pathway 36 1
Show member pathways
 12.62 VHL PDK1 MTOR HIF1A EPAS1 EP300
4
Translational Control 4
12.3 MTOR HIPK2 HIF1AN HIF1A EPAS1 EGLN1
5
p53 Signaling 63
Show member pathways
 12.13 PSMA7 HIPK2 HIF1A EP300
6
Thyroid hormone signaling pathway 36
11.85 MTOR HIF1A EP300
7
HIF-1 signaling pathway 36
11.85 VHL PDK1 MTOR HIF1A EP300 EGLN3
8
Angiogenesis (CST) 4
11.84 HIF1AN HIF1A EP300 EGLN1 ARNT
9
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.8 VHL HIF1A EPAS1 ARNT
10
HIF-1-alpha transcription factor network 1
11.72 HIF1A EP300 EGLN3 EGLN1 CITED2 ARNT
11
Central carbon metabolism in cancer 36
11.67 TIGAR PDK1 MTOR HIF1A
12
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.59 HIF1A EP300 ARNT
13
Notch-mediated HES/HEY network 1
11.4 HIF1A EP300 ARNT
14
Photodynamic therapy-induced HIF-1 survival signaling 1
11.38 HIF1AN HIF1A EGLN1 ARNT
15
HIF Repressors 64
Show member pathways
 11.36 HIF1AN HIF1A EPAS1 EP300 EGLN3 CITED2
16
HIF1Alpha Pathway 63
11.29 VHL PSMA7 HIF1AN HIF1A EP300 EGLN2
17
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha 1
10.98 VHL HIF3A HIF1AN HIF1A ARNT
18
Amplification and Expansion of Oncogenic Pathways as Metastatic Traits 1
10.81 VHL EPAS1
19
HIF-2-alpha transcription factor network 1
10.81 VHL HIF1AN EPAS1 EP300 EGLN3 EGLN2
20
miR-148a/miR-31/FIH1/HIF1andalpha;-Notch signaling in glioblastoma 1
10.53 HIF1AN HIF1A
Sources

GO Terms for Hypoxia

About this section

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.21 VHL TIGAR PSMA7 MTOR HIPK2 HIF3A
2 cytosol GO:0005829 9.97 VHL TIGAR PSMA7 MTOR KMT2A HILPDA
3 nucleus GO:0005634 9.86 VHL TIGAR PSMA7 MTOR KMT2A HIPK2
4 transcription factor complex GO:0005667 9.62 HIF1A EPAS1 EP300 ARNT
5 nucleoplasm GO:0005654 9.53 VHL PSMA7 PDK1 MTOR KMT2A HIPK2
6 RNA polymerase II transcription factor complex GO:0090575 9.43 HIPK2 HIF1A ARNT

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.15 VHL KMT2A HIF3A HIF1A EPAS1 EP300
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 KMT2A HIPK2 HIF3A HIF1A EPAS1 EP300
3 apoptotic process GO:0006915 10.01 TIGAR KMT2A HIPK2 HIF3A EP300 EGLN3
4 positive regulation of transcription, DNA-templated GO:0045893 10 VHL KMT2A HIPK2 HIF1A EP300 CITED2
5 post-translational protein modification GO:0043687 9.91 VHL PSMA7 HIF3A HIF1A EPAS1
6 transcription by RNA polymerase II GO:0006366 9.89 KMT2A HIF3A HIF1A EPAS1
7 response to hypoxia GO:0001666 9.81 HIF3A HIF1A EPAS1 EP300 EGLN3 EGLN2
8 positive regulation of endothelial cell proliferation GO:0001938 9.76 MTOR HIF1A ARNT
9 positive regulation of transforming growth factor beta receptor signaling pathway GO:0030511 9.65 HIPK2 EP300 CITED2
10 cellular response to hypoxia GO:0071456 9.65 TIGAR MTOR HYOU1 HIPK2 HILPDA HIF1A
11 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.62 HIF1A ARNT
12 embryonic placenta development GO:0001892 9.62 HIF1A EPAS1 CITED2 ARNT
13 mRNA transcription by RNA polymerase II GO:0042789 9.61 HIF1A ARNT
14 embryonic hemopoiesis GO:0035162 9.61 KMT2A HIF1A
15 embryonic camera-type eye morphogenesis GO:0048596 9.6 HIPK2 CITED2
16 iris morphogenesis GO:0061072 9.58 HIPK2 HIF1A
17 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 HIF1A EPAS1 ARNT
18 oxygen homeostasis GO:0032364 9.57 HIF1A EGLN1
19 voluntary musculoskeletal movement GO:0050882 9.56 MTOR HIPK2
20 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.56 P4HTM EGLN3 EGLN2 EGLN1
21 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.54 VHL HIF1AN CITED2
22 hypoxia-inducible factor-1alpha signaling pathway GO:0097411 9.52 PDK1 HIF1A
23 positive regulation of hormone biosynthetic process GO:0046886 9.49 HIF1A ARNT
24 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.36 VHL PSMA7 HIF3A HIF1AN HIF1A EPAS1

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.43 VHL TIGAR PSMA7 PDK1 MTOR KMT2A
2 oxidoreductase activity GO:0016491 9.95 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
3 transcription factor binding GO:0008134 9.91 VHL HIF1A EPAS1 EP300 ARNT
4 transcription coactivator activity GO:0003713 9.86 HIPK2 EP300 CITED2 ARNT
5 protein dimerization activity GO:0046983 9.84 HIF3A HIF1A EPAS1 ARNT
6 iron ion binding GO:0005506 9.8 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
7 dioxygenase activity GO:0051213 9.77 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.73 P4HTM EGLN3 EGLN2 EGLN1
9 RNA polymerase II activating transcription factor binding GO:0001102 9.7 HIPK2 EP300 CITED2
10 histone acetyltransferase binding GO:0035035 9.65 HIF1A EPAS1 CITED2
11 ferrous iron binding GO:0008198 9.62 HIF1AN EGLN3 EGLN2 EGLN1
12 oxygen sensor activity GO:0019826 9.49 HIF1AN EGLN2
13 L-ascorbic acid binding GO:0031418 9.46 P4HTM EGLN3 EGLN2 EGLN1
14 peptidyl-proline dioxygenase activity GO:0031543 9.43 EGLN3 EGLN2 EGLN1
15 peptidyl-proline 4-dioxygenase activity GO:0031545 9.13 EGLN3 EGLN2 EGLN1
16 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
Sources

Sources for Hypoxia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....